Benchmark Electronics Inc News Today

Analysts’ updated eps estimates for Monday, April 29th: Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by analysts at LADENBURG THALM/SH SH from a buy rating to a neutral rating. Altimmune (NASDAQ:ALT) was downgraded by analysts at Guggenheim from a buy rating to a neutral rating. Altair Engineering (NASDAQ:ALTR) had its neutral rating reaffirmed by analysts at Rosenblatt […]

Revenue Declines but Margins Improve; Free Cash Flow Remains Strong

/PRNewswire/ -- The medical device manufacturing outsourcing market is expected to grow by USD 46.24 billion from 2022 to 2027. In addition, the momentum of...

Revenue of $720 million, GAAP and non-GAAP earnings per share of $0.57

/PRNewswire/ -- The Adaptive Optics Market is projected to increase at a CAGR of 34.81% during the forecast period. One of the primary drivers behind the...

Loughborough, England, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today released its financial results for the quarter ended June 30, 2023 and provided a business update. Corporate Highlights: Previously announced initial patient data from UK...

Operator: Good day, and welcome to Benchmark Electronics Inc. Second Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions].

Loughborough, England, July 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company...

The electronic contract assembly market incremental growth recorded during (2023-2028) is $97.67 Billion. The shift toward electric vehicles (EVs) is...

The enzyme contract manufacturing market dynamics are anticipated to change in the coming years owing to the burgeoning...